Cube Pharmaceuticals: The sustained-release tablets of methylphenidate hydrochloride are expected to be on the market by the end of the third quarter of this year.

Cubic Pharmaceuticals stated on the Shenzhen Stock Exchange interactive platform that the slow-release methylphenidate hydrochloride tablets are expected to be launched at the end of the third quarter this year. During the period between approval and market launch, they have implemented comprehensive plans and preparations for commercialization, including market access, hospital admission, and professional promotion. The slow-release methylphenidate hydrochloride tablets adopt advanced three-layer osmotic pump controlled release technology, which achieves rapid efficacy through precise control release and effectively maintains stable efficacy throughout the day, consistent with the "FocusDart" formulation technology.